The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy

Melvin, David C.; Lee, Jenny K.; Belsey, E M; Arnold, Jason; Murphy, Robert L.

doi:10.1097/00002030-200003100-00023

Cited by 46 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver injury and increased ART toxicity may preclude patients coinfected with HIV and HCV from tolerating antiretroviral therapy. 21,22 Because the progression of HCV disease is exacerbated in the setting of HIV infection, 16 cause of death may be noted as being only HIV-related.…”

Section: Discussionmentioning

confidence: 99%

Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

Braitstein¹

2005

Canadian Medical Association Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

Braitstein¹

2005

Canadian Medical Association Journal

View full text Add to dashboard Cite

show abstract

“…6,9 Moreover, HCV coinfection was associated to treatment discontinuation and interruption. 1,3,14 The mechanism underlying the protective effect of hepatitis C in the risk of developing hyperlipidemia is not known, but might refl ect an impaired total cholesterol synthesis in the liver or total cholesterol hypercatabolism.…”

mentioning

confidence: 99%

Metabolic changes associated with antiretroviral therapy in HIV-positive patients

et al. 2009

View full text Add to dashboard Cite

OBJECTIVE:To evaluate metabolic changes associated with highly active antiretroviral therapy (HAART) in HIV-positive patients, and to identify risk factors associated. METHODS:Retrospective study that included 110 HIV-positive patients who where on HAART in the city of Porto Alegre (Southern Brazil) between January 2003 and March 2004. Data on demographic variables, cigarette smoking, diabetes mellitus, cholesterol and triglyceride levels, stage of HIV infection, antiretroviral therapy and HCV coinfection were collected. General linear models procedure for repeated measures was used to test the interaction between HAART and HCV coinfection or protease inhibitor treatment. RESULTS:Total cholesterol, triglycerides, and glucose levels signifi cantly increased after receiving HAART (p<0.001 for all variables), but no interaction with protease inhibitors was seen for total cholesterol, glucose and triglyceride levels (interaction treatment*protease inhibitors p=0.741, p=0.784, and p=0.081, respectively). An association between total cholesterol levels and HCV coinfection was found both at baseline and follow-up (effect of HCV coinfection, p=0.011). Glucose levels were increased by HAART (treatment effect, p=0.036), but the effect was associated to HCV coinfection (treatment*HCV effect, p=0.018). Gender, smoking habit, intravenous drug use and age were not signifi cantly associated with cholesterol, triglyceride and glucose changes. CONCLUSIONS:HCV-infected patients at baseline were signifi cantly less likely to develop hypercholesterolemia. The results provide further evidence of the role of HAART for the development of metabolic disturbances.

show abstract

“…The specific effects of HAART on HCV have been found to be both beneficial and detrimental. The increased risk of drug-induced hepatotoxicity in patients with concomitant HCV infection has been well documented and, as a consequence, coinfected patients are more likely to discontinue HAART [17]. Liver enzymes may also be elevated, with most reports focusing on severe elevations, both grade 3 (5 to 10 times the upper limit of normal [ULN]) and grade 4 (> 10 times ULN).…”

Section: Impact Of Antiretroviral Therapy On the Natural History And mentioning

confidence: 99%

Coinfection with hepatitis C virus and HIV: The challenges of management

Comar¹,

Sterling

2006

Curr hepatitis rep

View full text Add to dashboard Cite

The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy

Cited by 46 publications

References 11 publications

Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

Metabolic changes associated with antiretroviral therapy in HIV-positive patients

Coinfection with hepatitis C virus and HIV: The challenges of management

Contact Info

Product

Resources

About